The stock of Nuvation Bio Inc (NUVB) has seen a -7.61% decrease in the past week, with a -1.48% drop in the past month, and a 32.84% flourish in the past quarter. The volatility ratio for the week is 11.61%, and the volatility levels for the past 30 days are at 7.95% for NUVB. The simple moving average for the past 20 days is -3.09% for NUVB’s stock, with a -7.91% simple moving average for the past 200 days.
Is It Worth Investing in Nuvation Bio Inc (NYSE: NUVB) Right Now?
The 36-month beta value for NUVB is at 1.46. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NUVB is 229.10M, and currently, shorts hold a 9.14% of that float. The average trading volume for NUVB on January 14, 2025 was 2.33M shares.
NUVB) stock’s latest price update
The stock of Nuvation Bio Inc (NYSE: NUVB) has decreased by -3.96 when compared to last closing price of 2.78.Despite this, the company has seen a loss of -7.61% in its stock price over the last five trading days. businesswire.com reported 2025-01-06 that NEW YORK–(BUSINESS WIRE)–Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:00 a.m. PT in San Francisco, California. A live webcast of the presentation will be available on the Nuvation Bio website at https://investors.nuv.
Analysts’ Opinion of NUVB
Many brokerage firms have already submitted their reports for NUVB stocks, with Jefferies repeating the rating for NUVB by listing it as a “Buy.” The predicted price for NUVB in the upcoming period, according to Jefferies is $10 based on the research report published on March 27, 2024 of the previous year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see NUVB reach a price target of $5. The rating they have provided for NUVB stocks is “Buy” according to the report published on March 26th, 2024.
Jefferies gave a rating of “Hold” to NUVB, setting the target price at $2 in the report published on January 06th of the previous year.
NUVB Trading at -2.00% from the 50-Day Moving Average
After a stumble in the market that brought NUVB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.81% of loss for the given period.
Volatility was left at 7.95%, however, over the last 30 days, the volatility rate increased by 11.61%, as shares sank -0.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.14% upper at present.
During the last 5 trading sessions, NUVB fell by -7.61%, which changed the moving average for the period of 200-days by -7.29% in comparison to the 20-day moving average, which settled at $2.76. In addition, Nuvation Bio Inc saw 0.38% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NUVB starting from Wang Junyuan Jerry, who sale 56,361 shares at the price of $2.89 back on Nov 11 ’24. After this action, Wang Junyuan Jerry now owns 3,866,228 shares of Nuvation Bio Inc, valued at $162,883 using the latest closing price.
Mashal Robert, the Director of Nuvation Bio Inc, purchase 100,000 shares at $2.20 during a trade that took place back on Oct 08 ’24, which means that Mashal Robert is holding 100,000 shares at $220,000 based on the most recent closing price.
Stock Fundamentals for NUVB
Current profitability levels for the company are sitting at:
- -55.42 for the present operating margin
- -0.33 for the gross margin
The net margin for Nuvation Bio Inc stands at -219.41. The total capital return value is set at -0.26. Equity return is now at value -95.54, with -88.53 for asset returns.
Based on Nuvation Bio Inc (NUVB), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -9.71. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -26.64.
Currently, EBITDA for the company is -99.6 million with net debt to EBITDA at 0.03. When we switch over and look at the enterprise to sales, we see a ratio of 362.65. The receivables turnover for the company is 0.57for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.57.
Conclusion
In conclusion, Nuvation Bio Inc (NUVB) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
